drugset / Trial / NCT01322152

Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer

NCT01322152 ↗

Phase 2 Completed 52 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

The objectives of this study are to evaluate the efficacy and tolerability of single-week regimen of irinotecan plus capecitabine in the first-line or second-line treatment of advanced colorectal cancer.

Timeline

Start
2011-03
Primary completion
2013-05
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1200 mg/m2 Oral
Subject Irinotecan Small molecule 90 mg/m2 Intravenous

Indications